Fig. 3: In vivo characteristics of NARA1leukin.

a Mice received a single injection of hIL-2 (1 µg), hIL-2/NARA1 complexes (1 µg/5 µg), or NARA1leukin (0.5 µg or 1 µg hIL-2 equivalent). Blood samples were collected at the indicated time points and the presence of hIL-2 in serum was assessed using a sandwich ELISA coating anti-hIL-2 mAb 5344 and detecting with anti-hIL-2 mAb MAB202. Data are represented as mean ± SD of two independent experiments, n = 2–6 mice/group. b Experimental scheme. Mice received a single injection (arrowhead) of hIL-2 (1.5 µg), hIL-2/NARA1 complexes (1.5 µg/15 µg), or NARA1leukin (0.5 µg hIL-2 equivalent) and were assessed at indicated time points after the injection (h: hours, d: days). c–e Spleens were analyzed by flow cytometry to determine pSTAT5, Ki67, and total cell counts of CD8⁺ T cells (c), CD3^- NK1.1⁺ NK cells (d), and CD4⁺ CD25⁺ T cells (e). Differences between groups at the same time point were analyzed using two-way ANOVA followed by Tukey’s multiple comparison test (c–e). The comparisons of hIL-2/NARA1 and NARA1leukin to hIL-2 are indicated by asterisks (*), the differences between hIL-2/NARA1 and NARA1leukin are indicated by hashtags (#) on top of the columns; non-significant p-values are not indicated. (c) ****p < 0.0001, ^###p = 0.0002, **p = 0.0082 (d1) **p = 0.0085 (d2) ^#p = 0.0168. (d) ****p < 0.0001 ***p = 0.0006, ^##p = 0.0032 (2 h), *p = 0.0412 (pSTAT5), ^##p = 0.013 (d1), ^####p < 0.0001, *p = 0.0252 (Ki67) (e) ****p < 0.0001, ^####p < 0.0001, **p = 0.0016, *p = 0.0227 (d2), ^#p = 0.0302, *p = 0.0337 (d4). Data are presented as mean ± SD of three independent experiments, n = 5 mice/group. Source data are provided as a Source Data file.